Manus Neurodynamica: Catching Up With A 2022 Rising Leader

2022 was a turbulent year for start-ups, especially in medtech. However, Rutger Zietsma has persisted, refocused and is ready for further success with his company, Manus Neurodynamica.

Alzheimer's jigsaw
• Source: Shutterstock

Last year, Rutger Zietsma was named as one of In Vivo’s Rising Leaders thanks in part to his work driving the development and implementation of the NeuroMotor Pen, a handheld device that can be easily used by patients and clinicians to detect a variety of neurological abnormalities. At the time, Zietsma discussed the importance of selecting the right individuals to bring on board for a fledgling business and how the impact of a poor decision can be severe. 

Good decisions have clearly been made, though, as in the time since, Zietsma’s company, Manus Neurodynamica, has reached new heights....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rising Leaders

More from Leadership

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.